Related Experiment Video
Updated: Aug 29, 2025
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer
Nasrul Wathoni1,2, Lisa Efriani Puluhulawa1, I Made Joni2,3
1Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
Abstract:
Lung cancer is the second most common type of cancer after breast cancer. It ranks first in terms of mortality rate among all types of cancer. Lung cancer therapies are still being developed, one of which makes use of nanoparticle technology. However, conjugation with specific ligands capable of delivering drugs more precisely to cancer sites is still required to enhance nanoparticle targeting performance. Monoclonal antibodies are one type of mediator that can actively target nanoparticles. Due to the large number of antigens on the surface of cancer cells, monoclonal antibodies are widely used to deliver nanoparticles and improve drug targeting to cancer cells. Unfortunately, these antibodies have some drawbacks, such as rapid elimination, which results in a short half-life and ineffective dose. As a result, many of them are formulated in nanoparticles to minimize their major drawbacks and enhance drug targeting. This review summarizes and discusses articles on developing and applying various types of monoclonal antibody ligand nanoparticles as lung cancer target drugs. This review will serve as a guide for the choice of nanoparticle systems containing monoclonal antibody ligands for drug delivery in lung cancer therapy.
Insights
Monoclonal antibody ligands enhance nanoparticle drug delivery for lung cancer. Formulating these antibodies in nanoparticles overcomes limitations, improving targeted lung cancer therapy and patient outcomes.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Lung cancer is a leading cause of cancer mortality globally.
- Current therapies require enhanced targeting for improved efficacy.
- Nanoparticle technology offers potential for targeted drug delivery.
Purpose of the Study:
- To review and discuss monoclonal antibody (mAb) ligand nanoparticles for lung cancer therapy.
- To explore the development and application of these targeted drug delivery systems.
- To provide guidance on selecting appropriate nanoparticle systems for lung cancer treatment.
Main Methods:
- Literature review of studies on mAb ligand nanoparticles in lung cancer.
- Analysis of nanoparticle conjugation strategies with mAbs.
- Evaluation of drug delivery efficiency and targeting capabilities.
Main Results:
- Monoclonal antibodies serve as effective ligands for active nanoparticle targeting.
- Formulating mAbs in nanoparticles mitigates issues like rapid elimination and short half-life.
- mAb-conjugated nanoparticles demonstrate improved drug delivery to lung cancer sites.
Conclusions:
- Monoclonal antibody ligand nanoparticles represent a promising strategy for targeted lung cancer drug delivery.
- These systems offer a way to overcome limitations of traditional antibody-based therapies.
- Further research and development in this area can significantly advance lung cancer treatment options.
